MESOTHELIOMA

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors (like breast, ovarian, lung, and pancreatic cancers) that have no curative options. The main goal is to find safe doses and under…

This early-stage study tests an experimental drug called SGN-MesoC2 in 19 adults with advanced solid tumors (like lung, ovarian, or pancreatic cancer) that have not responded to standard treatments. The drug is designed to stick to cancer cells and kill them. The main goals are t…

This early-stage study tests the safety of a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or are hard to treat. The study involves 41 participants and will look at side effects and the right dose. It is not expected to …

This study tests an oral drug (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will be enrolled, and the study is currently on hold.

This early-stage study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, skin, kidney, and others. The main goal is to find the safest dose and understand side effects. About 126 participants will be enrolled to see if the tre…

This study tested the drug pembrolizumab in over 1,600 people with various advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink or control the tumors. The trial focused on identifying which patients were most likel…

This study aimed to test the drug alrizomadlin (APG-115) in people with a genetic condition called BAP1 cancer syndrome who had early-stage mesothelioma. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdrawn before any participan…

This early-phase study tests an oral drug called IAG933 in adults with advanced mesothelioma and certain other solid tumors that have specific genetic changes. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 137 participan…

This study tests a treatment using a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells with a protein called mesothelin. It is for people with malignant pleural disease, including mesothelioma and cancers that have spread to the chest lining. …

This study tests an experimental drug called HFB200301, alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find safe doses and check for side effects. About 72 people will take part, and the st…

This study tests a supportive care program for adults who have finished treatment for lung cancer or mesothelioma. The goal is to help improve quality of life during the transition to regular check-ups. About 21 participants will try the program, and researchers will see if it is…

This study collects blood, tumor tissue, and other body fluids from 1,000 adults with lung cancer, thymus cancer, or mesothelioma. Researchers analyze these samples to find biological markers that could predict how cancer will behave or respond to treatments. The goal is to impro…